drugset / Trial / NCT05964465

Mechanisms of Smell Improvement With Dupilumab.

NCT05964465

Phase 4 Completed 60 enrolled Medical University of South Carolina
NaSingle-groupOpen-labelTreatment

Summary

This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP). The investigators expect this study to provide convincing evidence that dupilumab improves clinical olfaction via direct reduction in olfactory cleft inflammation.

Timeline

Start
2023-08-10
Primary completion
2025-01-30
Completion
2025-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous